Lantheus Medical Imaging has finished enrolling patients for the Phase IV study of its contrast imaging agent Definity. The trial, called CaRES for Contrast Echocardiography REgistry for Safety Surveillance, will involve 1,060 patients across 15 locations in the U.S. and will collect data on patient demographics, safety monitoring results and any adverse events.

Related Summaries